Compare DNTH & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNTH | TFX |
|---|---|---|
| Founded | 2015 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2018 | 1994 |
| Metric | DNTH | TFX |
|---|---|---|
| Price | $86.57 | $133.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $121.00 | ★ $138.75 |
| AVG Volume (30 Days) | 422.6K | ★ 738.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,036,000.00 | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $15.97 |
| Revenue Next Year | $29.48 | $5.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.77 | $100.18 |
| 52 Week High | $96.50 | $139.67 |
| Indicator | DNTH | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 57.32 |
| Support Level | $82.00 | $102.20 |
| Resistance Level | $90.23 | $134.84 |
| Average True Range (ATR) | 4.58 | 4.26 |
| MACD | -0.20 | 0.02 |
| Stochastic Oscillator | 52.27 | 81.66 |
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.